Zacks.com on MSN7h
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...
STAT12h
Tris Pharma, looking to compete with Vertex, reports acute pain trial success
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Zacks.com on MSN14h
CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?
CRISPR Therapeutics AG (CRSP) shares rallied 6.5% in the last trading session to close at $44.20. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
My Top 5 Stocks to Buy in Early 2025
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...